Sinovac Biotech Ltd
SVA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001084201
No open-market purchases or sales by Sinovac Biotech Ltd insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 28
- 13F valueReported value at the end of Q2 2026
- $224.9M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SVA, Q2 2026
No superinvestor reported holding SVA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Sinovac Biotech Ltd insiders from Form 4, newest first.
No open-market purchases or sales by Sinovac Biotech Ltd insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Sinovac Biotech Ltd at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 2,718,735 | $184.5M | 3.49% | 00.0% | Unchanged |
| Vivo Capital, LLC | 5,903,000 | $38.2M | 3.49% | 00.0% | Unchanged |
| Neumann Advisory Hong Kong Ltd | 315,586 | $2.04M | 0.57% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 16,430 | $106.3K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9,146 | $59.2K | 0.00% | +20.0% | Added |
| Wells Fargo & Company | 4,580 | $29.6K | 0.00% | −231−4.8% | Reduced |
| UBS Group AG | 2,479 | $16.0K | 0.00% | +250+11.2% | Added |
| Harbour Investments, Inc. | 78 | $503 | 0.00% | −5−6.0% | Reduced |
| Horizon Investments, LLC | 52 | $336 | 0.00% | −52−50.0% | Reduced |
| Jones Financial Companies LLLP | 338 | $0 | 0.00% | 00.0% | Unchanged |